SEC Comment Letter 0000000000-25-003821 to Acurx Pharmaceuticals, Inc. (ACXP)
Acurx Pharmaceuticals, Inc.
Date: April 10, 2025 · CIK: 0001736243 · Accession: 0000000000-25-003821
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-286384
Letter
Re: Acurx Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed April 4, 2025 File No. 333-286384 Dear David P. Luci:
April 10, 2025
David P. Luci President and Chief Executive Officer Acurx Pharmaceuticals, Inc. 259 Liberty Avenue Staten Island, NY 10305
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jessica Dickerson at 202-551-8013 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Ivan K. Blumenthal, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> April 10, 2025 David P. Luci President and Chief Executive Officer Acurx Pharmaceuticals, Inc. 259 Liberty Avenue Staten Island, NY 10305 Re: Acurx Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed April 4, 2025 File No. 333-286384 Dear David P. Luci: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jessica Dickerson at 202-551-8013 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Ivan K. Blumenthal, Esq. </TEXT> </DOCUMENT>